Outcomes in CLL patients with NOTCH1 regulatory pathway mutations

Am J Hematol. 2021 Jun 1;96(6):E187-E189. doi: 10.1002/ajh.26140. Epub 2021 Mar 10.

Authors

Daniel R Helbig¹, Ghaith Abu-Zeinah¹, Erica Bhavsar¹, Paul J Christos², Richard R Furman¹, John N Allan¹

Affiliations

¹ Division of Hematology and Oncology, Weill Cornell Medical College, New York, New York.
² Department of Population Health Sciences, Weill Cornell Medical College, New York, New York.

PMID: 33625731
DOI: 10.1002/ajh.26140

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chromosomes, Human, Pair 12
DNA-Binding Proteins / genetics*
DNA-Binding Proteins / physiology
F-Box-WD Repeat-Containing Protein 7 / genetics*
F-Box-WD Repeat-Containing Protein 7 / physiology
Follow-Up Studies
Humans
Immunotherapy
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Mediator Complex / genetics*
Mediator Complex / physiology
Neoplasm Proteins / genetics*
Neoplasm Proteins / physiology
Prognosis
Progression-Free Survival
RNA-Binding Proteins / genetics*
RNA-Binding Proteins / physiology
Receptor, Notch1 / genetics*
Receptor, Notch1 / physiology
Signal Transduction / genetics*
Time-to-Treatment
Treatment Outcome
Trisomy
Watchful Waiting

Substances

DNA-Binding Proteins
F-Box-WD Repeat-Containing Protein 7
FBXW7 protein, human
MED12 protein, human
Mediator Complex
NOTCH1 protein, human
Neoplasm Proteins
RNA-Binding Proteins
Receptor, Notch1
SPEN protein, human